Study of Ravulizumab in Pediatric Participants With Primary IgAN

Phase 3 Recruiting 24 enrolled Alexion Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

Timeline

Start: 2025-06-14
Primary completion: 2028-07-12
Completion: 2029-11-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ravulizumab	Monoclonal antibody	—	Intravenous

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Summary

Timeline

Drugs

Indications